Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALUR Allurion Technologies	$2.26 -4.9%	$2.69	$2.15 ▼ $22.25	$17.68M	-0.45	68,969 shs	42,377 shs
DHAI DIH Holding US	$0.29 -3.9%	$0.25	$0.12 ▼ $2.93	$14.30M	0.07	12.78 million shs	9.93 million shs
IINN Inspira Technologies OXY B.H.N.	$1.23 -1.2%	$1.15	$0.40 ▼ $1.65	$15.71M	2.3	253,245 shs	9.20 million shs
QNRX Quoin Pharmaceuticals	$7.21 +0.8%	$8.27	$5.01 ▼ $54.95	$4.21M	1.44	4,502 shs	3,192 shs

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for August 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALUR Allurion Technologies	-5.05%	-12.09%	-27.72%	-20.49%	-86.41%
DHAI DIH Holding US	-3.94%	+15.49%	+16.98%	+32.47%	-88.06%
IINN Inspira Technologies OXY B.H.N.	-1.60%	-3.91%	-12.77%	+147.48%	+16.04%
QNRX Quoin Pharmaceuticals	+0.84%	-0.07%	-14.98%	-14.88%	-58.80%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALUR Allurion Technologies	2.3697 of 5 stars	3.4	5.0	1.0	0.0	0.6
DHAI DIH Holding US	0.3724 of 5 stars	0.0	3.0	1.1	1.7	0.0
IINN Inspira Technologies OXY B.H.N.	3.4038 of 5 stars	3.5	5.0	4.2	1.7	0.0
QNRX Quoin Pharmaceuticals	1.005 of 5 stars	0.0	4.0	2.3	0.8	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALUR Allurion Technologies	2.80	Moderate Buy	$22.83	912.56% Upside
DHAI DIH Holding US	0.00	N/A	N/A	N/A
IINN Inspira Technologies OXY B.H.N.	3.00	Buy	$2.00	62.60% Upside
QNRX Quoin Pharmaceuticals	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest QNRX, ALUR, IINN, and DHAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ALUR Allurion Technologies	Zacks Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold
6/2/2025	IINN Inspira Technologies OXY B.H.N.	Litchfield Hills Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
6/2/2025	IINN Inspira Technologies OXY B.H.N.	Litchfield Hills Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$2.00

(Data available from 8/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALUR Allurion Technologies	$28.30M	0.59	N/A	N/A	($30.08) per share	-0.07
DHAI DIH Holding US	$64.47M	0.21	N/A	N/A	($0.80) per share	-0.36
IINN Inspira Technologies OXY B.H.N.	N/A	N/A	N/A	N/A	$0.34 per share	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	$4.34 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALUR Allurion Technologies	-$26.15M	-$12.50	N/A	N/A	N/A	-86.05%	N/A	-41.49%	N/A
DHAI DIH Holding US	-$8.44M	-$0.30	N/A	∞	N/A	-13.59%	N/A	-25.97%	N/A
IINN Inspira Technologies OXY B.H.N.	-$11.05M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	-$8.96M	-$41.45	N/A	N/A	N/A	N/A	-210.50%	-99.41%	11/6/2025 (Estimated)

Latest QNRX, ALUR, IINN, and DHAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/7/2025	Q2 2025	QNRX Quoin Pharmaceuticals	-$6.83	-$6.28	+$0.55	-$6.28	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALUR Allurion Technologies	N/A	N/A	N/A	N/A	N/A
DHAI DIH Holding US	N/A	N/A	N/A	N/A	N/A
IINN Inspira Technologies OXY B.H.N.	N/A	N/A	N/A	N/A	N/A
QNRX Quoin Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALUR Allurion Technologies	N/A	2.09	1.88
DHAI DIH Holding US	N/A	0.51	0.34
IINN Inspira Technologies OXY B.H.N.	0.09	2.02	1.89
QNRX Quoin Pharmaceuticals	N/A	1.96	1.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALUR Allurion Technologies	21.39%
DHAI DIH Holding US	27.76%
IINN Inspira Technologies OXY B.H.N.	12.72%
QNRX Quoin Pharmaceuticals	8.63%

Insider Ownership

Company	Insider Ownership
ALUR Allurion Technologies	9.60%
DHAI DIH Holding US	49.58%
IINN Inspira Technologies OXY B.H.N.	29.40%
QNRX Quoin Pharmaceuticals	13.46%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALUR Allurion Technologies	501	7.46 million	6.74 million	Optionable
DHAI DIH Holding US	N/A	47.34 million	23.87 million	N/A
IINN Inspira Technologies OXY B.H.N.	20	12.62 million	8.91 million	Not Optionable
QNRX Quoin Pharmaceuticals	4	590,000	509,000	Not Optionable

QNRX, ALUR, IINN, and DHAI Headlines

Recent News About These Companies

Head-To-Head Review: Quoin Pharmaceuticals (NASDAQ:QNRX) and Rafael (NYSE:RFL)

August 20 at 2:27 AM | americanbankingnews.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

August 18 at 1:04 PM | finanznachrichten.de

Quoin Pharmaceuticals appoints Lawlor as Chief Financial Officer

August 18 at 1:04 PM | msn.com

Quoin Pharmaceuticals Appoints New Chief Financial Officer to Support Commercialization Strategy

August 18 at 8:30 AM | globenewswire.com

Quoin Pharmaceuticals Releases Fourth Episode in NETHERTON NOW Video Series Featuring International Patient Advocate Mandy Aldwin-Easton

August 12, 2025 | globenewswire.com

QNRX: Recent FDA & EMA Designations for QRX003 Potentially Could Accelerate Timeline

August 8, 2025 | finance.yahoo.com

Quoin (QNRX) Q2 Loss Beats Estimates

August 7, 2025 | fool.com

Quoin Pharmaceuticals stock rises after positive clinical updates

July 31, 2025 | investing.com

Quoin Pharmaceuticals, Inc.: Quoin Pharmaceuticals Provides Product Portfolio Update

July 29, 2025 | finanznachrichten.de

Quoin Pharmaceuticals Provides Product Portfolio Update

July 29, 2025 | globenewswire.com

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases - Morningstar

June 27, 2025 | morningstar.comM

Quoin Pharmaceuticals Releases New Episode of NETHERTON NOW Featuring Expert Insights on Netherton Syndrome - Nasdaq

June 27, 2025 | nasdaq.com

QNRX - Quoin Pharmaceuticals Ltd ADR Executives - Morningstar

June 26, 2025 | morningstar.comM

Quoin Pharmaceuticals Releases New NETHERTON NOW Video Featuring Professor Jemima Mellerio, International Expert in Genetic Skin Diseases

June 26, 2025 | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome - Yahoo Finance

June 25, 2025 | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Grants Rare Pediatric Disease Designation for QRX003 in Netherton Syndrome

June 24, 2025 | tmcnet.com

Quoin Pharmaceuticals, Ltd. (QNRX) - Yahoo Finance

June 24, 2025 | finance.yahoo.com

QNRX: With FDA Clearance to Initiate 2nd NS Whole Body Study for QRX003, Clinical Activities Expand Further

May 29, 2025 | finance.yahoo.com

Quoin Pharmaceuticals Announces FDA Clearance to Initiate Second Pivotal Whole Body QRX003 Netherton Syndrome Clinical Study

May 22, 2025 | manilatimes.netM

Quoin Pharmaceuticals Announces European Medicines Agency (EMA) Grants Orphan Drug Designation for QRX003 for the Treatment of Netherton Syndrome

May 20, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

QNRX, ALUR, IINN, and DHAI Company Descriptions

Allurion Technologies NYSE:ALUR

$2.26 -0.12 (-4.85%)

Closing price 08/19/2025 03:58 PM Eastern

Extended Trading

$2.24 -0.01 (-0.44%)

As of 07:27 AM Eastern

Allurion Technologies Inc. focuses on ending obesity with a weight loss platform to treat people who are overweight. Its platform, the Allurion Program, features swallowable and procedure-less intragastric balloon for weight loss (the Allurion Balloon), as well as offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion Virtual Care Suite. Allurion Technologies Inc. is headquartered in Natick, Massachusetts.

DIH Holding US NASDAQ:DHAI

$0.29 -0.01 (-3.94%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$0.28 -0.01 (-2.79%)

As of 07:41 AM Eastern

DIH Holding US, Inc. operates as a robotics and virtual reality (VR) technology provider for the rehabilitation industry in Europe, the Middle East, Africa, the United States, and the Asia Pacific. It offers ArmeoPower, a backbone robot for arm and hand therapy in an early stage of rehabilitation; ArmeoSpring for less severe patients that provides self-initiated repetitive arm and hand therapy in an extensive workspace; ArmeoSpring Pro; and Armeo Senso, for patients self-initiated and still structurally controlled movement patterns to completely open movement. The company also provides lower extremity products, including Erigo for gradual verticalization, leg mobilization, and intensive sensorimotor stimulation through cyclic leg loading; Lokomat, a robot-assisted therapy that enables training to increase the strength of muscles and a range of motion of joints in order to improve walking; Andago, a robotics smart control system that assists patients in walking naturally; C-Mill, creates a training environment; CAREN, a computer assisted rehabilitation environment; and GRAIL, an gait real-time analysis interactive lab solution for analysis training and research. In addition, it offers SafeGait, RYSEN, and M-Gait for gait and balance; and HocoNet and D-Flow software. DIH Holding US, Inc. was founded in 2021 and is based in Norwell, Massachusetts.

Inspira Technologies OXY B.H.N. NASDAQ:IINN

$1.23 -0.02 (-1.20%)

Closing price 08/19/2025 04:00 PM Eastern

Extended Trading

$1.24 +0.01 (+0.41%)

As of 07:18 AM Eastern

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels. The company was formerly known as Insense Medical Ltd. and changed its name to Inspira Technologies Oxy B.H.N. Ltd. in July 2020. Inspira Technologies Oxy B.H.N. Ltd. was incorporated in 2018 and is headquartered in Ra'annana, Israel.

Quoin Pharmaceuticals NASDAQ:QNRX

$7.21 +0.06 (+0.84%)

Closing price 08/19/2025 03:35 PM Eastern

Extended Trading

$7.16 -0.05 (-0.69%)

As of 08/19/2025 04:04 PM Eastern

Quoin Pharmaceuticals, Ltd., a clinical stage specialty pharmaceutical company, focuses on the development and commercialization of therapeutic products for rare and orphan diseases. Its lead product is QRX003, a topical lotion to treat Netherton Syndrome (NS). The company is also developing QRX004 for the treatment of recessive dystrophic epidermolysis bullosa; QRX007 to treat NS; and QRX008 for the treatment of scleroderma. It has a research agreement with Queensland University of Technology; a license agreement with Skinvisible Inc.; consulting agreements with Axella Research LLC; and a Master Service Agreement with Therapeutics Inc. The company was founded in 2018 and is based in Ashburn, Virginia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time